Genetics of Beta Cell Failure in Mexican Americans
Genetics of Beta Cell Failure in Mexican Americans
批准号:
8269634
负责人:
Thomas A Buchanan
金额:
$65.22万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-01-20 至 2014-10-31
关键词:
AffectAllelesAwardBeta CellBody CompositionBody fatCandidate Disease GeneCell physiologyCellsChronicClinicalCohort StudiesCross-Sectional StudiesDataData AnalysesDeteriorationDevelopmentDiabetes MellitusDietDietary HistoryDietary intakeDual-Energy X-Ray AbsorptiometryEarly treatmentEnvironmentEthnic groupFailureFamilyFinancial compensationFoodFrequenciesFutureGenesGeneticGenetic VariationGenotypeGestational DiabetesGlucose tolerance testGoalsHispanic AmericansHispanicsHyperglycemiaIndividualIndividual DifferencesInsulinInsulin ResistanceIntravenousLeadMedicalMexican AmericansNon-Insulin-Dependent Diabetes MellitusObesityOralPancreasPathway interactionsPhenotypePhysical activityPhysiologicalPopulationPregnancyPreventionRecruitment ActivityResearchResearch PersonnelResourcesSamplingSampling StudiesScanningSusceptibility GeneTestingVariantWomanbasecohortdesigndiabetes riskfallsgene environment interactiongene interactiongenetic associationglucose tolerancehigh risknovel strategiesprobandresponsetrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
The long-term objective of our research is to understand the mechanisms that cause type 2 diabetes (T2D) in
relatively young Hispanic Americans in order to develop better approaches to prediction, prevention and early
treatment. The specific objective of the BetaGene Study is to identify genes that predispose to T2D and
understand how those genes contribute to development of diabetes. In the first five years of BetaGene, we
performed oral (oGTT) and intravenous (ivGTT) glucose tolerance tests and body composition by DEXA on
1235 individuals from Mexican American families with probands who had either gestational diabetes (GDM) or
normal glucose tolerance during pregnancy. In a separate cohort of Hispanic women with prior GDM, we have
shown that T2D results from a progressive loss of pancreatic ¿-cell function that occurs over the course of
years on a background of chronic insulin resistance. The cross-sectional differences in ¿-cell function that we
and others have tested for association with putative T2D genes are, at best, surrogates for the more important
longitudinal changes. The primary hypothesis underlying this proposal is that one or more T2D genes
influence rates of change in ¿-cell compensation for insulin resistance. We provide strong evidence for
our hypothesis from preliminary studies of HNF4A. We will achieve three aims to test our hypothesis more
fully. First, we will recruit and re-phenotype a random longitudinal cohort of 400 individuals from the BetaGene
sample 3-5 years after their baseline exams. They will be our primary resource for association studies based
on changes in ¿-cell compensation. Second, we are already genotyping the entire BetaGene cohort for 20
genes for T2D and related quantitative traits. We will genotype the longitudinal cohort for relevant new genes
underlying T2D and T2D-related phenotypes as they are discovered and for a panel of ancestrally informative
markers to assess population substructure. Third, we will analyze data to test for association between variants
underlying T2D and T2D-related phenotypes and rates of change in ¿-cell compensation. We will also test for
interactions between genetic effects and aspects of the ¿-cell environment (e.g., obesity, insulin resistance,
diet, physical activity) on rates of change in ¿-cell compensation. Our results will provide unique information
about genetic influences on the primary physiological abnormality that causes T2D in young Hispanic
Americans. They will also provide unique information on the interplay among genetic variation and obesity,
insulin resistance and ¿-cell function. The information will help guide mechanistic studies of the genetic
contribution to diabetes. It will also provide a basis for new clinical approaches to diabetes prediction,
prevention and early treatment.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/oby.22128
发表时间:
2018-04
期刊:
Obesity (Silver Spring, Md.)
影响因子:
--
作者:
[Black MH, Shu YH, Wu J, Koebnick C, MacKay A, Watanabe RM, Buchanan TA, Xiang AH]
通讯作者:
Xiang AH
DOI:
10.1007/s00125-013-3121-8
发表时间:
2014-02
期刊:
DIABETOLOGIA
影响因子:
8.2
作者:
[Xiang, A. H., Watanabe, R. M., Buchanan, T. A.]
通讯作者:
Buchanan, T. A.
DOI:
10.1017/s0007114518002726
发表时间:
2018-12
期刊:
The British journal of nutrition
影响因子:
--
作者:
[Koebnick C, Black MH, Wu J, Shu YH, MacKay AW, Watanabe RM, Buchanan TA, Xiang AH]
通讯作者:
Xiang AH
Southern California Clinical and Translational Science Institute
-
批准号:10700623
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2023
-
负责人:Thomas A Buchanan
-
依托单位:
Southern California Clinical and Translational Science Institute
-
批准号:10559463
-
项目类别:
-
资助金额:$900.97万
-
财政年份:2016
-
负责人:Thomas A Buchanan
-
依托单位:
Southern California Clinical and Translational Institute
-
批准号:9929249
-
项目类别:
-
资助金额:$53.47万
-
财政年份:2016
-
负责人:Thomas A Buchanan
-
依托单位:
Southern California Clinical and Translational Science Institute
-
批准号:10613592
-
项目类别:
-
资助金额:$919.29万
-
财政年份:2016
-
负责人:Thomas A Buchanan
-
依托单位:
Southern California Clinical and Translational Science Institute
-
批准号:10381374
-
项目类别:
-
资助金额:$283.29万
-
财政年份:2016
-
负责人:Thomas A Buchanan
-
依托单位:
Beta Cell Restoration through Fat Mitigation
-
批准号:8897362
-
项目类别:
-
资助金额:$94.42万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
Beta Cell Restoration through Fat Mitigation
-
批准号:9109756
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
Beta Cell Restoration through Fat Mitigation
-
批准号:8247932
-
项目类别:
-
资助金额:$68.4万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
Beta Cell Restoration through Fat Mitigation
-
批准号:8535244
-
项目类别:
-
资助金额:$64.58万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
Beta Cell Restoration through Fat Mitigation
-
批准号:8703682
-
项目类别:
-
资助金额:$64.58万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH
-
批准号:8365141
-
项目类别:
-
资助金额:$152.84万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
-
批准号:8365140
-
项目类别:
-
资助金额:$152.84万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
-
批准号:8365143
-
项目类别:
-
资助金额:$53.78万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
-
批准号:8365142
-
项目类别:
-
资助金额:$53.78万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
LOS ANGELES BASIN CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE
-
批准号:8365144
-
项目类别:
-
资助金额:$662.28万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
Beta Cell Restoration through Fat Mitigation
-
批准号:8336920
-
项目类别:
-
资助金额:$66.56万
-
财政年份:2011
-
负责人:Thomas A Buchanan
-
依托单位:
Los Angeles Basin Clinical and Translational Science Institute
-
批准号:8101318
-
项目类别:
-
资助金额:$1028.84万
-
财政年份:2010
-
负责人:Thomas A Buchanan
-
依托单位:
Los Angeles Basin Clinical and Translational Science Institute
-
批准号:8101320
-
项目类别:
-
资助金额:$16.42万
-
财政年份:2010
-
负责人:Thomas A Buchanan
-
依托单位:
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
-
批准号:8173916
-
项目类别:
-
资助金额:$239.02万
-
财政年份:2010
-
负责人:Thomas A Buchanan
-
依托单位:
Southern California Clinical and Translational Science Institute
-
批准号:8655564
-
项目类别:
-
资助金额:$58.26万
-
财政年份:2010
-
负责人:Thomas A Buchanan
-
依托单位:
海外基金